Holista’s viral protection sanitiser products in demand
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Shares in Holista Colltech Limited (ASX:HCT) hit a high of 18 cents on Tuesday after the company announced that it had appointed OOH Medical Ltd as exclusive distributor for the NatshieldTM sanitiser products for the United Kingdom for an initial term of 3 years, with minimum orders for the first year to be negotiated in the coming weeks.
At one stage, the company’s shares were up nearly 10% which was a strong performance on a day when the broader market was down as much as 90 points.
OOH Medical shares common equity shareholders with Health Therapies LLC, the group’s exclusive distributor of NatshieldTM in the US.
The group has submitted an official tender application to supply NatshieldTM to the UK government.
Pending formal approval of this application, it will be conducting market research, test advertising and marketing to create and oversee promotional campaigns.
OOH Medical expects to receive registration of NatshieldTM from Medicines and Healthcare products Regulatory Agency, (MHRA) in the UK by July 2020.
With the registration and confirmation of all relevant legal and compliance procedures, OOH Medical will be able to market all NatshieldTM products through their distribution channels in the UK, including the NHS, e-commerce, health stores and pharmacies.
Holista’s March quarter cash inflows were nearly $2 million, up from approximately $1.7 million in the March quarter of 2019.
With the UK still in the grip of the coronavirus, there should be strong ongoing demand for Holista’s products.
Nasal sanitising balm effective against feline coronavirus
OOH Medical intends to distribute NatshieldTM products including a hand sanitiser and – upon commercialisation – a nasal-sanitising balm on which Holista is currently conducting research and development.
It is worth noting that today’s news comes less than a week after the company filed a global patent for a NatshieldTM nasal balm sanitiser.
This balm will contain Path-Away®, the plant-based anti-pathogenic solution, as the active ingredient.
Path-Away® had already been proven to be effective as a sanitiser against a broad range of viruses, bacteria and fungi.
On April 20, 2020, Holista announced that Path-Away® had been tested by a leading UK bio-safety laboratory to be more than 99.99% effective against the feline coronavirus, a surrogate of the COVID-19 novel coronavirus.
The formulation involves ingredients that will prolong and improve the effects of Path-Away®, within the nasal cavity.
Holista is accelerating development of NatshieldTM nasal balm sanitiser which will reduce the risk of viral infection via the nose, either via inhalation or touch (from hand to nose).
The nose is the easiest point of entry for viruses, being warm, damp and dark as well rich in fatty and amino acids.
The nasal passage opens directly into the sinuses, the throat and to the lungs.
The formulation of the nasal balm will be such that it is non-irritant, easily applied to the nose and can offer up to six hours of protection from viruses and infections.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.